$REGN
REGENERON PHARMACEUTICALS, INC.

2013 Q3 Form 10-Q Financial Statement

#000153217613000030 Filed on November 05, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2012 Q3
Revenue $597.0M $427.7M
YoY Change 39.59% 315.9%
Cost Of Revenue $28.25M $20.15M
YoY Change 40.25% 4376.67%
Gross Profit $568.8M $407.5M
YoY Change 39.56% 298.06%
Gross Profit Margin 95.27% 95.29%
Selling, General & Admin $97.61M $46.88M
YoY Change 108.19% 42.43%
% of Gross Profit 17.16% 11.5%
Research & Development $224.0M $158.3M
YoY Change 41.54% 23.74%
% of Gross Profit 39.39% 38.84%
Depreciation & Amortization $10.80M $9.400M
YoY Change 14.89% 13.25%
% of Gross Profit 1.9% 2.31%
Operating Expenses $321.7M $205.2M
YoY Change 56.77% 27.57%
Operating Profit $236.8M $202.4M
YoY Change 17.02% -446.18%
Interest Expense $11.74M $11.41M
YoY Change 2.83% 181.04%
% of Operating Profit 4.96% 5.64%
Other Income/Expense, Net -$11.12M -$10.90M
YoY Change 2.04% 225.64%
Pretax Income $225.7M $191.5M
YoY Change 17.87% -409.8%
Income Tax $84.38M
% Of Pretax Income 37.39%
Net Earnings $141.3M $191.5M
YoY Change -26.2% -407.01%
Net Earnings / Revenue 23.67% 44.77%
Basic Earnings Per Share $1.44 $2.02
Diluted Earnings Per Share $1.25 $1.72
COMMON SHARES
Basic Shares Outstanding 98.23M shares 95.01M shares
Diluted Shares Outstanding 116.7M shares 115.8M shares

Balance Sheet

Concept 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $445.0M $263.0M
YoY Change 69.2% 7.35%
Cash & Equivalents $263.2M $119.0M
Short-Term Investments $182.0M $144.0M
Other Short-Term Assets $144.0M $55.00M
YoY Change 161.82% 243.75%
Inventory $63.29M $29.57M
Prepaid Expenses
Receivables $855.8M $506.7M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.634B $948.6M
YoY Change 72.27% 179.0%
LONG-TERM ASSETS
Property, Plant & Equipment $453.9M $372.9M
YoY Change 21.71% 2.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $330.0M $313.0M
YoY Change 5.43% 21.32%
Other Assets $4.409M $18.32M
YoY Change -75.94% -12.75%
Total Long-Term Assets $1.006B $712.0M
YoY Change 41.33% 10.73%
TOTAL ASSETS
Total Short-Term Assets $1.634B $948.6M
Total Long-Term Assets $1.006B $712.0M
Total Assets $2.640B $1.661B
YoY Change 59.0% 68.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $31.00M $22.00M
YoY Change 40.91% 4.76%
Accrued Expenses $188.0M $102.0M
YoY Change 84.31% 75.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $268.7M $178.6M
YoY Change 50.49% 34.26%
LONG-TERM LIABILITIES
Long-Term Debt $481.0M $450.0M
YoY Change 6.89% 183.02%
Other Long-Term Liabilities $10.57M $6.987M
YoY Change 51.32% -97.33%
Total Long-Term Liabilities $10.57M $6.987M
YoY Change 51.32% -98.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $268.7M $178.6M
Total Long-Term Liabilities $10.57M $6.987M
Total Liabilities $950.2M $854.6M
YoY Change 11.19% 53.98%
SHAREHOLDERS EQUITY
Retained Earnings -$189.5M -$987.5M
YoY Change -80.81%
Common Stock $94.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.690B $806.0M
YoY Change
Total Liabilities & Shareholders Equity $2.640B $1.661B
YoY Change 59.0% 68.93%

Cashflow Statement

Concept 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income $141.3M $191.5M
YoY Change -26.2% -407.01%
Depreciation, Depletion And Amortization $10.80M $9.400M
YoY Change 14.89% 13.25%
Cash From Operating Activities $92.50M -$2.400M
YoY Change -3954.17% -94.87%
INVESTING ACTIVITIES
Capital Expenditures -$31.60M -$10.30M
YoY Change 206.8% 15.73%
Acquisitions
YoY Change
Other Investing Activities -$182.8M -$38.50M
YoY Change 374.81% -581.25%
Cash From Investing Activities -$214.4M -$48.80M
YoY Change 339.34% 5322.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.600M -1.800M
YoY Change -300.0% 500.0%
NET CHANGE
Cash From Operating Activities 92.50M -2.400M
Cash From Investing Activities -214.4M -48.80M
Cash From Financing Activities 3.600M -1.800M
Net Change In Cash -118.3M -53.00M
YoY Change 123.21% 10.42%
FREE CASH FLOW
Cash From Operating Activities $92.50M -$2.400M
Capital Expenditures -$31.60M -$10.30M
Free Cash Flow $124.1M $7.900M
YoY Change 1470.89% -120.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
26701000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
48308000 USD
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
111345000 USD
CY2013Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
219138000 USD
CY2012Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
38934000 USD
CY2013Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
31194000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
593207000 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
855844000 USD
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2851000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1166000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1763508000 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1882421000 USD
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
97840000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
166358000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
71475000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
144808000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63507000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-447662000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-20689000 USD
CY2013Q3 us-gaap Assets
Assets
2640415000 USD
CY2012Q4 us-gaap Assets
Assets
2080490000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
1206012000 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
1634160000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
354990000 USD
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
66835000 USD
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
63442000 USD
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
3393000 USD
CY2013Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
509733000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
351565000 USD
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
354958000 USD
CY2013Q3 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
500000 USD
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
1000000 USD
CY2013Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0 USD
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
702000 USD
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
651000 USD
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2
702000 USD
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2
51000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
670000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230276000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263211000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118998000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
483610000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
32935000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-364612000 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
141884000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
325871000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
279820000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
191935000 USD
CY2013Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
7700000 USD
CY2012Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
296518000 USD
CY2013Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
314162000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
54286000 USD
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
20145000 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
28253000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
83557000 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
360225000 USD
us-gaap Costs And Expenses
CostsAndExpenses
946378000 USD
us-gaap Costs And Expenses
CostsAndExpenses
651832000 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
225323000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
82890000 USD
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
34929000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33809000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
131822000 USD
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
111893000 USD
CY2013Q3 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
39174000 USD
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
148134000 USD
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
192022000 USD
CY2013Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
218092000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27162000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29912000 USD
CY2013Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
136980000 USD
CY2012Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
99913000 USD
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.36
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.95
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.72
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.364
CY2013Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.374
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.043
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19987000 USD
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
68928000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
97840000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
191468000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
279862000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
515207000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
225684000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
187651000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
84378000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
29231000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
94894000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
299704000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
498236000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-28605000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20815000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
84109000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
71244000 USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
518000 USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
USD
CY2012Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1154000 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2885000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2556000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
652000 shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4761000 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4761000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4761000 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10379000 shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14106000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10220000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14080000 shares
CY2013Q3 us-gaap Interest Expense
InterestExpense
11736000 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
11413000 USD
us-gaap Interest Expense
InterestExpense
34776000 USD
us-gaap Interest Expense
InterestExpense
33809000 USD
CY2013Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
4678000 USD
CY2012Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
7374000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
13857000 USD
CY2013Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12322000 USD
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2570000 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
63292000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
28638000 USD
CY2013Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5225000 USD
CY2012Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4862000 USD
CY2013Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
5100000 USD
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3600000 USD
CY2012Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
14656000 USD
CY2013Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
34837000 USD
us-gaap Inventory Write Down
InventoryWriteDown
8600000 USD
us-gaap Inventory Write Down
InventoryWriteDown
4800000 USD
CY2013Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
618000 USD
CY2012Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
517000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2028000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1628000 USD
CY2013Q3 us-gaap Liabilities
Liabilities
950244000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
835105000 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2640415000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2080490000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
163550000 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
268727000 USD
CY2013Q3 us-gaap Licenses Revenue
LicensesRevenue
5893000 USD
us-gaap Licenses Revenue
LicensesRevenue
17679000 USD
us-gaap Licenses Revenue
LicensesRevenue
17679000 USD
CY2012Q3 us-gaap Licenses Revenue
LicensesRevenue
5893000 USD
CY2013Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
182112000 USD
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
77819000 USD
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
271230000 USD
CY2013Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
329863000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-24636000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-28425000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-172176000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-245507000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-167800000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
306867000 USD
us-gaap Net Income Loss
NetIncomeLoss
327556000 USD
us-gaap Net Income Loss
NetIncomeLoss
279862000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
141306000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
191468000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
145984000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
198842000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
279862000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
341413000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32181000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32748000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11118000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10896000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
547955000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
312043000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
236802000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
202364000 USD
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38319000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19569000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23100000 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4409000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1685000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
578000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000 USD
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
467000 USD
CY2013Q3 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
10908000 USD
CY2012Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
6550000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7259000 USD
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10573000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-15710000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-13636000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
166358000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
477312000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
398253000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
71475000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
34175000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
87347000 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
156839000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
56663000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48440000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41718000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
260770000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
319152000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379940000 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
453891000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1601000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1625000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
158295000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
224045000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
591807000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
444530000 USD
CY2012Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
8186000 USD
CY2013Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189498000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-517054000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
319035000 USD
CY2012Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
145042000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
319161000 USD
CY2013Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
134359000 USD
us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. </font></div></div>
CY2013Q3 us-gaap Revenues
Revenues
597027000 USD
us-gaap Revenues
Revenues
963875000 USD
CY2012Q3 us-gaap Revenues
Revenues
427687000 USD
us-gaap Revenues
Revenues
1494333000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
3148000 USD
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
879000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
2231000 USD
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
1074000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
576622000 USD
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
249172000 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
367118000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1019751000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
247330000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46883000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
97607000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
153016000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
63385000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
143217000 USD
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
shares
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48440000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42625000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1245385000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
1690171000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
485732000 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
806024000 USD
CY2013Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
24760000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
134594000 USD
CY2012Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
18826000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
65526000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
59592000 USD
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
18487000 shares
CY2012Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20818000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15431000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
17952000 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116713000 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115830000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115554000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109780000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94349000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98226000 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95012000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97602000 shares
CY2011Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
6200000 USD
CY2012Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
7000000 USD
CY2013Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
18400000 USD
CY2012Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
8600000 USD
CY2012Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
10985000 USD
CY2013Q3 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
24407000 USD
CY2012Q4 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
21870000 USD
CY2013Q3 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
56290000 USD
CY2012Q3 regn Costofcollaborationmanufacturing1
Costofcollaborationmanufacturing1
USD
regn Costofcollaborationmanufacturing1
Costofcollaborationmanufacturing1
USD
CY2013Q3 regn Costofcollaborationmanufacturing1
Costofcollaborationmanufacturing1
10320000 USD
regn Costofcollaborationmanufacturing1
Costofcollaborationmanufacturing1
23684000 USD
CY2012Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
17022000 USD
CY2013Q3 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
13866000 USD
CY2012Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
76520000 USD
CY2013Q3 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
77670000 USD
CY2013Q3 regn Facility Lease Obligation Including Reimbursements
FacilityLeaseObligationIncludingReimbursements
7700000 USD
CY2012Q4 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
1374000 USD
CY2013Q3 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
794000 USD
CY2012Q4 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
159436000 USD
CY2013Q3 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
167219000 USD
CY2013Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
462000 shares
CY2012Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
797000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
415000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
699000 shares
regn Non Cash Interest Expense
NonCashInterestExpense
17316000 USD
regn Non Cash Interest Expense
NonCashInterestExpense
17009000 USD
CY2013Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
88583000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC

Files In Submission

Name View Source Status
0001532176-13-000030-index-headers.html Edgar Link pending
0001532176-13-000030-index.html Edgar Link pending
0001532176-13-000030.txt Edgar Link pending
0001532176-13-000030-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-20130930.xml Edgar Link completed
regn-20130930.xsd Edgar Link pending
regn-20130930_cal.xml Edgar Link unprocessable
regn-20130930_def.xml Edgar Link unprocessable
regn-20130930_lab.xml Edgar Link unprocessable
regn-20130930_pre.xml Edgar Link unprocessable
regn-93013x10q.htm Edgar Link pending
regn-ex_311x9302013x10q.htm Edgar Link pending
regn-ex_312x9302013x10q.htm Edgar Link pending
regn-ex_32x9302013x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending